Developed at one of the world’s leading medical image fusion research teams, SmartTarget offers an easy to use, state of the art system for precision targeting of prostate cancer.

SmartTarget

Target Accurately

  • Bespoke algorithms enforce realistic deformation of MR model
  • Mathematically best-fit image fusion
  • Live needle guidance mode enables precise positioning
  • 3D visualisation ensures max length tumour core targeting

Target Simply

  • Clinician-designed User Interface
  • Intuitive workflow
  • Fast & easy ultrasound contouring
  • Works with any ultrasound manufacturer
  • Radiologist-friendly MR contouring

Target Smarter

  • Transperineal approach reduces infection risk
  • Unique prostate MRI database underpins mathematical shape model
  • Machine learning techniques assure accurate deformation 
  • Core technology on method and modelling protected by worldwide patents

Evidence is mounting rapidly with regards to the patient benefit of a prostate cancer care pathway guided by MR imaging and targeted biopsy.  Clinicians at University College London Hospitals have been working over the past five years with researchers in UCL’s Centre for Medical Image Computing to develop an image fusion software for transperineal targeting of the prostate. The resulting CE-marked SmartTarget® device is specifically designed to be agnostic to the clinic’s MR and ultrasound equipment, intuitive for the user, fast to set up and slipping easily into existing clinical workflows with minimal disruption. Having also benefitted from funding by the UK’s Department of Health and the Wellcome Trust, we are pleased to offer a system that is affordable for both the public and private healthcare sectors.

Please contact us today to arrange a demonstration or speak to us further about the benefits and credentials of the SmartTarget® system.

Step 1

Planning: contoured MR image identifies areas of suspicious tissue.

Step 2

Modelling: our patented technology creates anatomically accurate deformable model of prostate and tumour(s).

Step 3

Fusion: model mapped accurately to dynamic ultrasound image giving augmented visibility of tumour location enabling  precision targeting.

“The SmartTarget image fusion software works extremely well for me. It is accurate, swift and very easy to use, for both transperineal local and sedation biopsies. Additionally, the same software very nicely guides focal therapy – we have tried it with a number of ablative modalities.”

Mr Hashim Ahmed, Honorary Consultant Urological Surgeon, UCL Hospitals

News and Events

SmartTarget announces product launch

London, 30th September 2016 SmartTarget Ltd announces the launch of its new device for the detection of prostate cancer. The...

Launching at BAUS16

SmartTarget Ltd are pleased to announce their CE-marked device for transperineal fusion biopsy will be formally launched as a market-ready...

Book a demo with our team now